Tiffany Wang

Tiffany Wang, MD, MBA, MS, currently serves as the Executive Medical Director at Aktis Oncology, a role assumed in October 2024. Prior to this, Tiffany held positions including Vice President of Clinical Development at Tango Therapeutics and Senior Medical Director of Clinical Development at Omega Therapeutics, focusing on oncology, epigenomics, and mRNA technologies. With extensive experience at Ipsen, Tiffany contributed as Medical Development Director and Core Member of the Onyvide Development Team, along with roles in biometrics and oncology biostatistics. Tiffany's earlier career included significant statistical positions at Eli Lilly and Company and ImClone Systems, emphasizing early phase oncology and clinical data management. Educational qualifications comprise an MD in Clinical Medicine from Capital University of Medical Sciences, an MBA from the Indiana University Kelley School of Business, and dual Master’s degrees in Statistics and Biochemistry and Molecular Biology from The University of Georgia.